PCN74 Long-Term Cost-Effectiveness of Nadofaragene Firadenovec and Oportuzumab Monatox for Treatment of Bacillus Calmette-Guerin (BCG)-Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC)
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.166
https://www.valueinhealthjournal.com/article/S1098-3015(21)00383-1/fulltext
Title :
PCN74 Long-Term Cost-Effectiveness of Nadofaragene Firadenovec and Oportuzumab Monatox for Treatment of Bacillus Calmette-Guerin (BCG)-Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00383-1&doi=10.1016/j.jval.2021.04.166
First page :
Section Title :
Open access? :
No
Section Order :
10748